

**PERSONAL INFORMATION**

Place of Birth: Seattle, Washington  
Spouse: Ellen Li, M.D., Ph.D.

**CITIZENSHIP**

U.S.A.

**ADDRESS**

Office of the President  
Stony Brook University  
310 Administration Building  
Stony Brook, NY 11794  
(631) 632-6265 • (631) 632-6621

**PRESENT POSITION**

President, Stony Brook University

**EDUCATION**

1976 B.A., Biological Sciences, The College of the University of Chicago, IL  
1980 M.D., Medicine, Harvard University Medical School, Cambridge, MA  
1984-1987 Post-doctoral, Immunology, Washington University School of Medicine, St. Louis, MO

**ACADEMIC POSITIONS/EMPLOYMENT**

1976 Teaching Assistant in Biology, The College of the University of Chicago, IL  
1980-1981 Medical Intern, Massachusetts General Hospital, Boston, MA  
1981-1983 Medical Resident, Massachusetts General Hospital, Boston, MA  
1983-1984 Fellow in Infectious Diseases, Washington University School of Medicine, St. Louis, MO  
1985-1988 Pfizer Fellow in Microbiology and Immunology, Washington University School of Medicine, St. Louis, MO  
1987-1988 Instructor in Medicine, Washington University School of Medicine, St. Louis, MO  
1988 Assistant Professor, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO  
1989 Assistant Professor, Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO  
1990-2009 Chief Medical Consultant, BarnesCare Travelers Clinic  
1993-1999 Associate Professor (with tenure), Department of Medicine, Washington University School of Medicine, St. Louis, MO  
1994-2004 Associate Professor, Department of Molecular Microbiology  
1999-2009 Professor, Department of Medicine, Washington University School of Medicine, St. Louis, MO  
2003-2009 Director, Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research  
2004-2009 Professor, Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO  
2006-2009 Vice Chancellor for Research, Washington University in Saint Louis, MO  
2009- Professor of Medicine, Stony Brook University School of Medicine, Stony Brook, NY  
2009- President, Stony Brook University, Stony Brook, NY

**UNIVERSITY AND HOSPITAL APPOINTMENTS AND COMMITTEES**

1987-2006 Attending physician, Internal Medicine and Infectious Diseases, Barnes-Jewish Hospital of St. Louis  
Chief Medical Consultant, BarnesCare Travelers Clinic  
1989 Chairman, Committee to Formulate a Health Policy for Washington University Personnel Who Work with Animals

1992-2000 Member, Washington University MA/MD Committee  
 1992-2001 Program Committee, American Society of Tropical Medicine and Hygiene  
 1995-1997 At-large Representative, Washington University Faculty Senate  
 Member, Senate Council of Washington University  
 Member, Advisory Committee on Academic Freedom and Tenure  
 1997-1999 Faculty Representative, Washington University Benefits Committee  
 1999-2004 Selection Committee and Advisory Board Medical Student International Fellowships  
 2000-2002 Clinical Representative to the Executive Faculty, Washington University School of Medicine  
 2000-2004 Chairman, Institutional Biological and Chemical Safety Committee  
 2001-2002 Division of Biology and Biomedical Sciences Graduate Admissions Committee  
 2006-2008 Chairman, Research Strategic Planning for Washington University School of Medicine  
 2007-2009 Chairman, Skandalaris Center Research Planning Committee  
 2009- Governing Body, Stony Brook University Hospital, Stony Brook, NY

#### **MEDICAL LICENSURE AND BOARD CERTIFICATION**

Massachusetts License 1980-1983  
 Missouri License 1983-present  
 American Board of Internal Medicine, Certification in Internal Medicine 1983  
 American Board of Internal Medicine, Certification in Infectious Diseases 1986

#### **MILITARY SERVICE**

None

#### **HONORS AND AWARDS**

1976 Honors in Biological Sciences, University of Chicago  
 1976 Phi Beta Kappa, University of Chicago  
 1979 Albert Schweitzer Fellow of Harvard Medical School  
 1985-1988 Pfizer Postdoctoral Fellow  
 1994-1999 Research Career Development Award, NIH  
 1999-2004 Burroughs-Wellcome Scholar in Molecular Parasitology  
 2000 Distinguished Service Teaching Award—Washington University School of Medicine  
 2002-2004 Permanent member, Tropical Medicine and Parasitology Study Section  
 2004-2006 Permanent member, Eukaryotic Pathogenesis Study Section  
 2005-2006 Excellence in Mentoring, Washington University School of Medicine  
 2006 Distinguished Service Award, Washington University Medical Center Alumni Association  
 2007-2008 Ambassador, Paul G. Rogers Society for Global Health Research  
 2009 Honorary Doctorate Degree, Konkuk University, Seoul, Korea  
 2009 Honoree, VIBS (Victims Information Bureau of Suffolk)  
 2010 Long Island Association Small Business Education Advocate Award  
 2010 Thomas Hartman Humanitarian Award  
 2010 The Influentials: *Long Island Business News* Top 20 Agents of Change  
 2012 Three Village Man of the Year  
 2012, 2013, 2015 *Long Island Press*, Best College President  
 2013 David Award Honoree  
 2014 EOP (Educational Opportunity Program) Champion  
 2014 American Heart Association Distinguished Leadership Honoree

## COMMUNITY AND REGIONAL RESPONSIBILITIES

2006-2009 Board of Directors, Center for Emerging Technologies  
2006-2009 Board Member, Research Alliance of Missouri  
2006-2009 Board of Trustees, Saint Louis Academy of Science  
2007-2009 Board Member, St. Louis Center of Excellence, Missouri Life Sciences Trust Fund  
2009- Board of Trustees, Cold Spring Harbor Laboratory  
2009- Board of Directors, The Research Foundation of SUNY  
2009- Board of Directors, Goodwill Industries of Greater NY and Northern NJ  
2009- Board of Directors, Long Island Association  
2010- Education Working Group member for United States Senator Kirsten Gillibrand  
2011 Health and Education Transition Committee member for New York Governor Andrew Cuomo  
2011- Long Island Regional Economic Development Council  
2012- Board of Directors, Accelerate Long Island  
2013- Board Member, New York Genome Center

## NATIONAL BOARDS AND PANELS

National Science Advisory Board for Biosecurity (NSABB), Criteria Roundtable Adviser, June 2006  
NIH Blue Ribbon Panel on the New England Infectious Diseases Research Laboratory, 2008-2012  
NIH National Advisory Allergy & Infectious Diseases Council, 2008-2012  
U.S. Department of Commerce, Emerging Technology and Research Advisory Committee, 2008-2010  
America East Conference Board of Presidents, 2009-  
Board of Directors, Brookhaven Science Associates, 2009-  
Chairman, Board of Directors, Brookhaven Science Associates, 2010  
National Security Higher Education Advisory Board, 2011-  
Chair, America East Conference Board of Presidents, 2012-2015  
Chair, NIH National Science Advisory Board for Biosecurity, 2012-  
Association of Public and Land-Grant Universities, Board of Directors, 2012-  
Chair, Universities Research Association Council of Presidents, 2014  
NCAA Division I Board of Directors, 2014-

## PROFESSIONAL SOCIETIES AND ORGANIZATIONS

Associate Member American College of Physicians, 1981  
Member, Infectious Disease Society of America, 1989  
Member, American Society of Tropical Medicine and Hygiene, 1988  
Member, American Federation for Clinical Research, 1989  
Member, American Society for Microbiology, 1992  
Fellow, Infectious Disease Society of America, 1995  
Member, American Society for Clinical Investigation, 1995  
Secretary-Treasurer, Board of Directors, Infectious Diseases Society of St. Louis, 2004-2007

## EDITORIAL AND REVIEW RESPONSIBILITIES

### *Editorial Board:*

Infection and Immunity 1998-2003

### *Ad hoc reviewer for:*

New England Journal of Medicine	Vaccine
Clinical Infectious Diseases	Parasite Immunology
Journal of Infectious Diseases	Experimental Parasitology
Molecular Microbiology	Lancet

Gastroenterology  
Physiological Reviews  
Cellular Microbiology  
PNAS  
Acta Tropica

Journal of Parasitology  
Am.J.Tropical Medicine and Hygiene  
Laboratory Animal Science  
Molecular and Biochemical Parasitology  
Nature

*Ad hoc grant reviewer for:*

Wellcome Trust  
International Center for Diarrhoeal Disease Research  
USAID  
American Federation for AIDS Research  
NIH—SEPs on TDRU program  
Temporary member: NIH-TMP study section 10-2000, 6-2002  
EpScor NSF Site Visit Team 2005

*Educational Accreditation:*

Chair, University of California, Santa Cruz accreditation team for Western Association of Schools & Colleges (WASC), 2015

**OPINION EDITORIALS AND ESSAYS**

*Newsday*: Stanley: Protect Research Institutions from Sequestration—and Beyond, October 2012  
*Newsday*: How Will the Sequester Affect You? Long Island Institutions Respond, February 2013  
*Huffington Post*: College Cost and Student Loan Debt, June 2013  
*Huffington Post*: Federal Investment in Research Still Essential, April 2014  
*Huffington Post*: 70 Years After the GI Bill, We Need a Similar Investment, June 2014  
*Newsday*: A Sure Way to Attack Deadly Ebola, September 2014  
*Huffington Post*: Protect and Maintain America's Scientific Preeminence, December 2014  
*Huffington Post*: Investing in America's Dazzling Scientific Talent, December 2014  
*Huffington Post*: How Best to Hold Federal Scientific Research Accountable, January 2015  
*Huffington Post*: The Changing Politics and Consistent Science of Vaccinations, March 2015  
*Huffington Post*: The Changing Politics and Consistent Science of Vaccinations, March 2015  
*Scientific American*: Give Young Scientists the Keys to the Lab, October 2015

**MAJOR INVITED LECTURES**

*Visiting scientist and lecturer*—Centro de Investigacion y de Estudios Avanzados del IPN, Mexico City, Mexico, March 1991  
“Molecular approach to *Entamoeba histolytica* pathogenesis.” St. Louis University, April 1991  
*Chair*—Amebiasis Session, American Society Tropical Medicine Hygiene—“Isolation of an *Entamoeba histolytica* cDNA clone encoding a protein with a zinc finger domain.” Boston, November 1991  
*Keynote Speaker*—“Role of the amebic cysteine proteinase in amebic liver abscess formation.” Meeting of the Society of Biological Chemistry, Zacatecas, Mexico, November 1994  
*Co-chair and Speaker*—Merck Symposium on Amebiasis: “New models for amebiasis.” ASTMH Meeting, Cincinnati, November 1994  
*Speaker*—“Scid mouse model of amebiasis” and “Scid mice and gene knockout mice as models for parasitic disease.” India/U.S.A. Joint Vaccine Action Program, Lucknow, India, December 1994  
*Speaker*—“What can murine models tell us about the immunobiology of amebiasis?” Berne Immunology Center, University of Virginia, Charlottesville, December 1994  
*Speaker*—“Progress in a vaccine for amebiasis.” European Conference on Tropical Medicine, Hamburg, Germany, November 1995  
*Chair and Speaker*—Symposium: “New insights into the immunobiology of parasitic diseases from knockout and scid mice.” ASTMH Meeting, December 1996

*Speaker*—Bernardo Sepulveda Molecular Biology Seminar, XIII Congress on Amebiasis, Mexico City, Mexico, January 1997

*Speaker*—Keystone Symposium on Cellular and Molecular Cross Talk at Mucosal Surfaces, Santa Fe, New Mexico, March 1997

*Speaker*—“EhADH2 enzyme: A novel target for anti-amebic drugs.” ICTDR Conference, Washington, D.C., April 1997

*Speaker*—“Oral and DNA vaccines to prevent amebiasis.” ICTDR Conference, Washington, D.C., April 1998

*Speaker*—“How intestinal epithelial cells regulate the inflammatory response to enteric pathogens.” University of Texas Health Sciences Center, San Antonio, Texas, June 1998

*Visiting professor and speaker*—“Amebiasis: Putting man into mouse to understand an ancient enemy.” New York University Medical Center Grand Rounds, January 1999

*Speaker*—“Pathways for amebic induction of inflammation and programmed cell death.” Burroughs Wellcome Symposium, ASTMH Meeting, Washington, D.C., November 1999

*Speaker*—“Pathways for amoebic induction of inflammation and tissue damage.” International Symposium on Amoebiasis, Hamburg, Germany, July 2000

*Speaker*—National Institutes of Health/National Institute for Allergic and Infectious Diseases, “Amebic dysentery and ICE.” April 2001

*Speaker*—St. Louis University, “Amebic dysentery and ICE.” September 2001

*Speaker*—University of Texas at El Paso, “Amebic dysentery and ICE.” October 2001

*Speaker*—Southern Illinois University at Carbondale, “Amebic dysentery and ICE.” October 2001

*Speaker*—Washington University School of Medicine, Department of Pediatrics Grand Rounds, “Amebiasis: new insights into an ancient enemy.” October 2001

*Chairman and speaker*—Session on Amebiasis: Ellison Foundation Conference on Tropical Diseases, Bhubaneswar, India, February 2002

*Speaker*—Woods Hole Tropical Medicine and Parasitology Course: “Amebiasis.” July 2002, July 2003

*Speaker*—Plenary Session, X International Conference on Parasitology, Vancouver, B.C. “Pathways for amebic induction of inflammation and programmed cell death.” August 2002

*Speaker*—Special Symposium in Honor of Jean Hickman: “New insights into amebiasis from SCID-HU-INT mice.” ASTMH Meeting, Denver, November 2002

*Speaker*—“Role of TNF in amebic induced inflammation.” EMBO Conference on Amebiasis, Paris, France, March 2003

*Speaker*—Engineering Connections Series: “SARS and other emerging infectious diseases—the dangers of a small world.” Washington University, September 2003

*Speaker*—Yonsei University, Challenges in the Post Genomic Era: “Simultaneous host/pathogen genomics.” November 2003

*Speaker*—Korean Society of Parasitology: “Pathways for amebic induction of inflammation and programmed cell death.” November 2003

*Speaker*—Institute Pasteur: “New insights into dysentery from SCID-HU-INT mice.” November 2003

*Speaker*—University of Illinois, Emerging Infectious Diseases Conference: “Pathogenesis of amebiasis.” March 2004

*Speaker*—University of Pennsylvania, Parasitology Group: “Understanding amebiasis from the host and pathogen perspective.” November 2004

*Speaker*—Washington University School of Medicine, Medical Grand Rounds: “Emerging Infectious Diseases—Preparing for the Unexpected and the Inevitable.” November 2004

*Speaker*—7th Annual Conference on Hemophilia, San Juan, Puerto Rico, “Emerging Infections: Preparing for the unexpected and the inevitable.” February 2005

*Speaker*—NIAID/NIDDK Workshop on Humanized Mouse Models of Disease. Washington, D.C.

*Speaker*—ASM Biodefense Meeting, Washington, D.C.: “Chimeric SCID-Human Mice to Study Enteric Pathogens.” February 2006

*Speaker*—MMI/ID Seminar Series: “Molecular Dissection of *Entamoeba Histolytica* Pathogenesis.” March 2006

*Speaker*—Washington University Reunion Medical Update: “Avian Influenza & Emerging Infectious Diseases.” May 2006

*Speaker*—Washington University Reunion College: “The Threat of Emerging Infectious Diseases, Avian Influenza and Beyond.” May 2006

*Speaker*—Pathobiology of human diseases series: Biodefense and the immunogenetics of smallpox vaccination. Washington University, May 2007

*Speaker*—IGCC-Public Policy and Biological Threats: Training the Next Generation; “*Basics of Viral Pathogenesis and Disease*.” La Jolla, California, July 2007

*Speaker*—13th Annual Kentucky EPSCoR Statewide Conference. “Perspectives and lessons-learned in building academic team science.” Lexington, Kentucky, October 2007

*Speaker*—5th Annual MRCE Meeting, Washington University. “Immunogenetics of Smallpox Vaccination.” St. Louis, MO, October 2007

*Speaker*—IGCC-Public Policy and Biological Threats: Training the Next Generation; “*Basics of Viral Pathogenesis and Disease*.” La Jolla, California, July 2008

*Speaker*—Institute for Public Health, *International Public Health Activities at Washington University in St. Louis*, Washington University, September 2008

*Speaker*—Tradeline, Inc., Academic Medical & Health Science Centers 2008; “*Key program and facility initiatives to grow disease-focused research and funding*.” San Francisco, California, October 2008

*Speaker*—“Global Health is America’s Health–National Security.” University of Missouri-Columbia, February 2009

*Speaker*—“Fueling Local Economies: Research, Innovation and Jobs,” U.S. Congress Joint Economic Committee Hearing, Washington, D.C., June 2010

*Speaker*—“Challenges for Public Education in the United States and China,” Zuel University, Wuhan, China, April 2011

*Speaker*—APLU Panel: “Continuing Research Amidst Fiscal Restraint,” November 2012

*Speaker*—Gain-of-Function Research on Highly Pathogenic Avian Influenza H5N1 Viruses: An International Consultative Workshop, Washington, D.C., December 2012

*Speaker*—Dual Use Research of Concern, CICG, Geneva, Switzerland, February 2013

*Speaker*—AAAS-AAU-APLU-FBI Meeting, “Setting the Stage: Biological Research in Today’s Global Research Environment,” Washington, D.C., February 2013

*Speaker*—National Institutional Biosafety Committees Conference, Seattle, Washington, June 2013

*Speaker*—APLU Annual Meeting, “Working with State Governments: Understanding Higher Education Budgets to Maximize Investments,” November 2014

*Speaker*—Adelphi University, “Ebola and Beyond: Are We Ready?” November 2014

*Presentation*—National Science Advisory Board for Biosecurity (NSABB); National Research Council and Institute of Medicine of the National Academies, December 2014

*Speaker*—AAU Panel, “Sustaining the Biomedical Research Enterprise: Mapping a Course for the Future” April 2015

#### **PAST RESEARCH SUPPORT**

Principal Investigator, U54 AI057160-01, “Midwest Regional Center for Excellence in Biodefense and Emerging Infectious Diseases Research,” 09/01/03 to 03/01/14, Direct costs: \$5,123,000/year

Principal Investigator, NIAID R01 AI-30084, “Molecular Dissection of *Entamoeba histolytica* pathogenesis,” 7/01/95 to 1/31/2011, Direct costs: \$250,000

Co-Investigator, 1UL1RR024992-01 (Kenneth Polonsky, M.D., Principle Investigator) Washington University Institute of Clinical and Translational Sciences (CTSA), Co-Director; Tracking and Evaluation Program, 9/17/07 to 5/31/12, Annual funds: \$6,818,890

Principal Investigator, Pathways of inflammation and tissue damage in amebiasis, Burroughs Wellcome Scholar in Molecular Parasitology, 7/1/99 to 6/30/06, Total direct costs: \$425,000

Principal Investigator, NIAID R01 AI-51621-01 “Structure-Function of *Entamoeba* alcohol dehydrogenase 2,” 5/01/02 to 3/31/06, Direct costs: \$200,000/year

Principal Investigator, 1C06RR029841-01, “An Animal Biosafety Level 3 Laboratory for Stony Brook University,” 3/25/10 to 6/30/15, NIH National Center for Research, \$14,179,569

#### **CURRENT RESEARCH SUPPORT**

Principal Investigator, NSF, Leveraging SUNY LSAMP to Build Better STEM Pathways and Prepare Global STEM Scholars, 7/2011 to 7/2016, Total Award Amount: \$2,521,815

## CLINICAL TITLE AND RESPONSIBILITIES

Attending physician, Red Medical Service, Barnes Hospital, 1989 to 2007

Attending physician, Infectious Diseases Service, Barnes-Jewish Hospital, 1987 to 2007

Chief Medical Consultant, BarnesCare Travelers Clinic, 1990 to 2009

## TEACHING TITLE AND RESPONSIBILITIES

Lecturer, Washington University School of Medicine, 1st-Year Course in Microbiology “Introduction to Tropical Medicine”

Lecturer, Washington University School of Medicine, 2nd-Year Course in Pathophysiology of Infectious Diseases “Bacteremia and Sepsis,” “Protozoa I, Protozoa III,” and “Cases in Tropical Medicine”

Lecturer, Infectious Diseases and the Diagnostic Laboratory Course, “Intestinal Protozoa”

Lecturer, Clinical Infectious Diseases Course, “Diarrheal Diseases,” “Diseases of Travelers,” and “Bacteremia and Sepsis,” “Tropical Diseases”

Lecturer, Lucille P. Markey Special Emphasis Pathway in Human Pathobiology, “Vaccines for Malaria”

Lecturer, Microbial Pathogenesis Course, “MDR genes and pathogenesis”

Lecturer, Molecular Mechanisms of Disease Course, “Vaccines against parasitic diseases”

Instructor, Case Problems in Cell Biology and Biochemistry

Instructor, Tropical Medicine Course

Faculty advisor, International Health and Tropical Medicine Forum

Lecturer, Barnes Housestaff Conference, “Diseases of Travelers”

Lecturer, Microbiology 1st-year Graduate Student Course: “Protozoan taxonomy and diversity”

Lecturer, Honors Class, The Global Challenge of Infectious Diseases, Fall 2012, Stony Brook University

Lecturer, Honors Class, The 21st Century University, Fall 2013, Stony Brook University

Lecturer, Honors Class, The Continuing Challenge of Infectious Diseases, Spring 2015, Stony Brook University

## PUBLICATIONS

### PEER-REVIEWED

1. Wong, YC; **Stanley Jr, SL**; Garber, BB. Separation and characterization of neuronal and glial cell populations from embryonic chick cerebra in culture. *Anatomischer Anzeiger*; 1981; 150(4):351-373.
2. **Stanley Jr, SL**; Kehl, O. Ascending paralysis associated with diethylcarbamazine treatment of a *M. loa loa* infection. *Tropical Doctor*; 1982, January; 12(1):16-19.
3. **Stanley Jr, SL**; Lusk, R. Thoracic actinomycosis presenting as a brachial plexus syndrome. *Thorax*, 1985, January; 40(1):74-75.
4. Powderly, WG; **Stanley Jr, SL**; Medoff, G. Pneumococcal endocarditis: Report of a series and review of the literature. *Review of Infectious Diseases*, 1986; 8:786-789.
5. **Stanley Jr, SL**; Bischoff, JK; Davie, JM. Antigen induced rheumatoid factors: Protein and carbohydrate antigens induce different rheumatoid factor responses. *Journal of Immunology*, 1987; 139:2936-2942.
6. **Stanley Jr, SL**; Li, E; Davie, JM. Antigen induced rheumatoid factors: Characterization of monoclonal rheumatoid factors produced after protein and carbohydrate immunization. *Molecular Immunology*, 1988, March; 25(3):285-294.
7. Li, E; Becker, A; **Stanley Jr, SL**. Use of Chinese hamster ovary cells with altered glycosylation patterns to define the carbohydrate specificity of *Entamoeba histolytica* adhesion. *Journal of Experimental Medicine*, 1988, May; 167(5):1725-1730.
8. Li, E; Becker, A; **Stanley Jr, SL**. Chinese hamster ovary cells deficient in N-acetylglucosaminyltransferase I activity are resistant to *Entamoeba histolytica*-mediated cytotoxicity. *Infection & Immunity*, 1989; 57:8-12.
9. **Stanley Jr, SL**; Becker, A; Kunz-Jenkins, C; Foster, L; Li, E. Cloning and expression of a membrane antigen of *Entamoeba histolytica* possessing multiple tandem repeats. *Proceedings of the National Academy of Sciences of the USA*, 1990, July 1; 87(13):4976-4980.
10. Burch, DJ; Li, E; Reed, S; Jackson, TFHG; **Stanley Jr, SL**. Isolation of a strain-specific *Entamoeba histolytica* cDNA clone. *Journal of Clinical Microbiology*, 1991; 29:696-701.

11. **Stanley Jr, SL;** Jackson, TFHG; Reed, SL; Calderon, J; Kunz-Jenkins, C; Gathiram, V; Li, E. Serodiagnosis of invasive amebiasis using a recombinant *Entamoeba histolytica* protein. *JAMA*, 1991, October; 266(14):1984-1986.
12. **Stanley Jr, SL;** Foster, L; Phillips, N. Molecular analysis of carbohydrate antigen induced monoclonal IgM anti-IgG antibodies (rheumatoid factors). *Molecular Immunology*, 1992, April; 29(4):453-61.
13. **Stanley Jr, SL;** Huizenga, H; Li, E. Isolation and partial characterization of a surface glycoconjugate of *Entamoeba histolytica*. *Molecular & Biochemical Parasitology*, 1992; 50:127-138.
14. **Stanley Jr, SL;** Li, E. Isolation of an *Entamoeba histolytica* cDNA clone encoding a protein with a putative zinc finger domain. *Molecular & Biochemical Parasitology*, 1992; 50:185-188.
15. Li, E; Kunz-Jenkins, C; **Stanley Jr, SL.** Isolation and characterization of genomic clones encoding a serine-rich *Entamoeba histolytica* protein. *Molecular & Biochemical Parasitology*, 1992; 50:355-358.
16. Cieslak, PR; **Stanley Jr, SL.** Advances in amebiasis: implications for the clinician. *Infectious Diseases in Clinical Practice*, 1992; 1(3):151-157.
17. Zhang, Y; Li, E; Jackson, TFHG; Zhang, T; Gathiram, V; **Stanley Jr, SL.** Use of a recombinant 170 kDa surface antigen of *Entamoeba histolytica* in serodiagnosis of amebiasis, and identification of immunodominant domains of the native molecule. *Journal of Clinical Microbiology*, 1992, November; 30(11):2788-2792.
18. Cieslak, PR; Virgin IV, HW; **Stanley Jr, SL.** A severe combined immunodeficient (SCID) mouse model for infection with *Entamoeba histolytica*. *Journal of Experimental Medicine*, 1992, December; 176(6):1605-1609.
19. Myung, K; Burch, DJ; Jackson, TFHG; **Stanley Jr, SL.** Serodiagnosis of invasive amebiasis using a recombinant *Entamoeba histolytica*-antigen based ELISA. *Archives of Medical Research*, 1992; 23(2):285-288.
20. Zhang, Y; Aley, S; **Stanley Jr, SL;** Gillin, FD. Cysteine-dependent zinc binding by membrane proteins of *Giardia lamblia*. *Infection & Immunity*, 1993; 61:520-524.
21. Cieslak, PR; Zhang, T; **Stanley Jr, SL.** Expression of a recombinant *Entamoeba histolytica* antigen in a *Salmonella typhimurium* vaccine strain. *Vaccine*, 1993; 11:773-776.
22. Zhang, Y; Li, E; **Stanley Jr, SL.** *Entamoeba histolytica*: The EHZc3 cDNA clone encodes a zinc-binding protein. *Experimental Parasitology*, 1993, Aug; 77(1):118-120.
23. Zhang, T; Cieslak, PR; Foster, L; Kunz-Jenkins, C; **Stanley Jr, SL.** Antibodies to the serine rich *Entamoeba histolytica* protein (SREHP) prevent amebic liver abscess in severe combined immunodeficient (SCID) mice. *Parasite Immunology*, 1994, May; 16(5):225-230.
24. Zhang, T; Cieslak, PR; **Stanley Jr, SL.** Protection of gerbils from amebic liver abscess by immunization with a recombinant *Entamoeba histolytica* antigen. *Infection & Immunity*, 1994, April; 62(4):1166-70.
25. Yang, W; Li, E; Kairong, T; **Stanley Jr, SL.** *Entamoeba histolytica* has an alcohol dehydrogenase homologous to the *adhE* gene product of *Escherichia coli*. *Molecular & Biochemical Parasitology*, 1994; 64:253-260.
26. Zhang, T; **Stanley Jr, SL.** Protection of gerbils from amebic liver abscess by immunization with a recombinant protein derived from the 170 kDa adhesin of *Entamoeba histolytica*. *Infection & Immunity*, 1994; 62(6):2605-2608.
27. Li, E; Stenson, WF; Kunz-Jenkins, C; Swanson, PE; Duncan, R; **Stanley Jr, SL.** *Entamoeba histolytica* interactions with polarized human intestinal Caco-2 epithelial cells. *Infection & Immunity*, 1994; 64(11):5112-5119.
28. **Stanley Jr, SL;** Tian, K; Koester, JP; Li, E. The serine rich *Entamoeba histolytica* protein (SREHP) is a phosphorylated membrane protein containing O-linked terminal N-acetylglucosamine (O-GlcNAc) residues. *Journal of Biological Chemistry*, 1995, February; 270(8):4121-4126.
29. **Stanley Jr, SL;** Blanchard, JL; Johnson, N; Foster, L; Kunz-Jenkins, C; Zhang, T; Tian, K; Cogswell, FB. Immunogenicity of the recombinant serine rich *Entamoeba histolytica* protein (SREHP) amebiasis vaccine in the African Green Monkey. *Vaccine*, 1995, July; 13(10):947-951.
30. Zhang, T; Li, E; **Stanley Jr, SL.** Oral immunization with the dodecapeptide repeat of the serine rich *Entamoeba histolytica* protein (SREHP) fused to the cholera toxin B subunit induces a mucosal and systemic anti-SREHP antibody response. *Infection & Immunity*. 1995, April; 63(4):1349-1355.
31. **Stanley Jr, SL;** Zhang, T; Rubin, D; Li, E. Role of the amebic cysteine proteinase in amebic liver abscess in severe combined immunodeficient (SCID) mice. *Infection & Immunity*, 1995, April; 63(4):1587-1590.
32. Velazquez, C; Valette, I; Cruz, M; Labra, M-L; Montes, J; **Stanley Jr, SL;** Calderon, J. Identification of immunogenic epitopes of the 170-kDa subunit adhesin of *Entamoeba histolytica* in patients with invasive amebiasis. *Journal of Eukaryotic Microbiology*, 1995, September; 42(5):636-641.
33. Li, E; Yang, W-G; Zhang, T; **Stanley Jr, SL.** Interaction of laminin with *Entamoeba histolytica* cysteine proteinases and its effect on amebic pathogenesis. *Infection & Immunity*. 1995, October; 63(10):4150-4153.

34. Flores, BM; **Stanley Jr, SL**; Yong, TS; Ali, M; Diedrich, DL; Torian, BE. Surface localization, regulation, and biologic properties of the 96-kDa alcohol/aldehyde dehydrogenase (EhADH2) of pathogenic *Entamoeba histolytica*. *Journal of Infectious Diseases*, 1996, January; 173(1):226-231.
35. Yong, TS; Li, E; Clark, D; **Stanley Jr, SL**. Complementation of a *Escherichia coli adhE* mutant by the *Entamoeba histolytica EhADH2* gene provides a method for the identification of new anti-amebic drugs. *Proceedings of the National Academy of Sciences of the USA*, 1996, June 25; 93(13):6464-6469.
36. Seydel, KB; Braun, K; Zhang, T; Jackson, TFHG; **Stanley Jr, SL**. Human anti-amebic antibodies provide protection against amebic liver abscess formation in the SCID mouse. *The American Journal of Tropical Medicine & Hygiene*, 1996; 55:330-332.
37. Zhang, T; **Stanley Jr, SL**. Oral immunization with an attenuated vaccine strain of *Salmonella typhimurium* expressing the serine rich *Entamoeba histolytica* protein induces an anti-amebic immune response and protects gerbils from amebic liver disease. *Infection & Immunity*, 1996, May; 64(5):1526-1531.
38. Seydel, KB; Li, E; **Stanley Jr, SL**. Human intestinal epithelial cells produce pro-inflammatory cytokines in response to infection in a SCID-HU-INT model of amebiasis. *Infection & Immunity*, 1997, May; 65(5):1631-1639.
39. Lotter, H; Zhang, T; Seydel, KB; **Stanley Jr, SL**; Tannich, E. Identification of an epitope on the *Entamoeba histolytica* 170 kDa-lectin conferring antibody mediated protection against invasive amebiasis. *Journal of Experimental Medicine*, 1997, May 19 185(10):1793-1801.
40. Ryan, ET; Butterson, JR; Zhang, T; **Stanley Jr, SL**; Calderwood, SB. Oral immunization with attenuated vaccine strains of *Vibrio cholerae* expressing a dodecapeptide repeat of the serine rich *Entamoeba histolytica* protein fused to the cholera toxin B subunit induces systemic and mucosal anti-amebic and anti-*V. cholerae* antibody responses in mice. *Infection & Immunity*, 1997, August; 65(8):3118-3125.
41. Seydel, KB; Zhang, T; **Stanley Jr, SL**. Neutrophils play a critical role in early resistance to amebic liver abscess in SCID mice. *Infection & Immunity*, 1997, September; 65(9):3951-3953.
42. Zhang, T; **Stanley Jr, SL** Expression of the serine rich *Entamoeba histolytica* protein (SREHP) in the avirulent vaccine strain *Salmonella typhi* TY2x4297  $\Delta$ cytA  $\Delta$ crp  $\Delta$ asd: Safety and immunogenicity in mice. *Vaccine*, 1997, August-September; 15(12-13): 1319-1322.
43. Marinets, A; Zhang, T; Guillen, N; Gounon, P; Bohle, B; Vollman, U; Scheiner, O; Wiedermann, G; **Stanley Jr, SL**; Duchene, M. Protection against invasive amoebiasis by a single monoclonal antibody directed against a lipophosphoglycan antigen localized on the surface of *Entamoeba histolytica*. *Journal of Experimental Medicine*, 1997; 186:1557-1565.
44. Wang, L; Calderon, J; **Stanley Jr, SL**. Identification of B cell epitopes in the serine rich *Entamoeba histolytica* protein. *The American Journal of Tropical Medicine & Hygiene*, 1997, December; 57(6):723-726.
45. **Stanley Jr, SL**; Jackson, TFHG; Foster, L; Singh, S. Longitudinal study of the antibody response to recombinant *Entamoeba histolytica* antigens in patients with amebic liver abscess. *The American Journal of Tropical Medicine & Hygiene*, 1998, April; 58(4):414-416.
46. Sultan, F; Jin-L-l; Jobling, MG; Holmes, RK; **Stanley Jr, SL**. Mucosal immunogenicity of a holotoxin-like molecule containing the serine rich *Entamoeba histolytica* protein (SREHP) fused to the A<sub>2</sub> domain of cholera toxin. *Infection & Immunity*, 1998, February; 66(2):462-468.
47. Seydel, KB; Zhang, T; Champion, GA; Fichtenbaum, C; Swanson, PE; Tzipori, S; Griffiths, JK; **Stanley Jr, SL**. *Cryptosporidium parvum* infection induces human TNF $\alpha$  and IL-8 production from human intestinal xenografts in SCID mice. *Infection & Immunity*, 1998; 66:2379-2398.
48. Seydel, KB; **Stanley Jr, SL**. *Entamoeba histolytica* induces host cell death in amebic liver abscess by a non-Fas, non-TNF $\alpha$ -dependent pathway of apoptosis. *Infection & Immunity*, 1998 June; 66(6):2980-2983.
49. Seydel, KB; Li, E; Zhang, Z; **Stanley Jr, SL**. Epithelial cell-initiated inflammation plays a crucial role in early tissue damage in amebic infection of human intestine. *Gastroenterology*, 1998, December; 115(6):1446-1453.
50. Temesvari, LA; Harris, EN; **Stanley Jr, SL**; Cardelli, JA. Early and late endosomal compartments of *Entamoeba histolytica* are enriched in cysteine proteinases, acid phosphatases and several Ras-related Rab GTPases. *Molecular & Biochemical Parasitology*, 1999; 103:225-241.
51. Zhang, T; **Stanley Jr, SL**. DNA vaccination with the serine rich *Entamoeba histolytica* protein (SREHP) prevents amebic liver abscess in rodent models of disease. *Vaccine*, 1999, December 10; 18(9-10):868-874.
52. Seydel, KB; Smith, SJ; **Stanley Jr, SL**. Interferon-gamma and nitric oxide are required for host defense in a murine model of amebic liver abscess. *Infection & Immunity*, 2000; 68:400-402.
53. Lotter, H; Khajawa, F; **Stanley Jr, SL**; Tannich, E. Protection of gerbils from amebic liver abscess by vaccination with a 25 mer peptide derived from the "cysteine-rich" region of the *Entamoeba histolytica* galactose-specific adherence lectin. *Infection & Immunity*, 2000; 68:4416-4421.

54. Zhang, Z; Yan, L; Wang, L; Seydel, KB; Li, E; Ankri, S; Mirelman, D; **Stanley Jr, SL**. *Emtamoeba histolytica* cysteine proteinases with interleukin-1 beta converting enzyme (ICE) activity cause intestinal inflammation and tissue damage in amebiasis. *Molecular Microbiology*, 2000, August; 37(3):542-548.
55. Zhang, Z; Jin, L; Champion, G; Seydel, KB; **Stanley Jr, SL**. Shigella infection in SCID-HU-INT mice: role for neutrophils in containing bacterial dissemination in human intestine. *Infection & Immunity*, 2001; 69:3240-3247.
56. Stenson, W; Zhang, Z; Riehl, T; **Stanley Jr, SL**. Amebic infection induces cyclooxygenase-2 (COX-2) production in human intestine. *Infection & Immunity*, 2001; 69:3382-3388.
57. Espinosa, A; Yan, L; Zhang, Z; Foster, L; Clark, D; Li, E; **Stanley Jr, SL**. The bifunctional *Entamoeba histolytica* alcohol dehydrogenase 2 (EhADH2) protein is necessary for amebic growth and survival and requires an intact C-terminal domain for both alcohol dehydrogenase and acetaldehyde dehydrogenase activity. *Journal of Biological Chemistry*, 2001, June 8; 276(23): 20136-20143.
58. Babcock, HM; Ritchie, DJ; Christiansen, E; Starlin, R; Little, R; **Stanley Jr, SL**. Successful treatment of vancomycin-resistant *Enterococcus endocarditis* with oral linezolid. *Clinical Infectious Diseases*, 2001, May 1; 32(9):1373-1375.
59. Yan, L; **Stanley Jr, SL**. Blockade of caspases inhibits amebic liver abscess formation in a mouse model of disease. *Infection & Immunity*, 2001; 69:7911-7914.
60. Zhang, Z; Duchene, M; **Stanley Jr, SL**. A monoclonal antibody to the amebic lipophosphoglycan-proteophosphoglycan antigens can prevent disease in human intestinal xenografts infected with *Entamoeba histolytica*. *Infection & Immunity*, 2002, October; 70(10):5873-5876.
61. Zhang, Z; Mahajan, S; Zhang, XC; **Stanley Jr, SL**. Tumor necrosis factor—alpha is a key mediator of the gut inflammation seen in amebic colitis in human intestine in the SCID mouse-human intestinal xenograft model of disease. *Infection & Immunity*, 2003, September; 71(9):5355-5359.
62. Zhang, XC; Zhang, Z; Alexander D; Bracha, R; Mirelman, D; **Stanley Jr, SL**. Expression of amoebapores is required for full expression of *Entamoeba histolytica* virulence in amebic liver abscess, but is not necessary for the induction of inflammation or tissue damage in amebic colitis. *Infection & Immunity*, 2004, February; 72(2):678-683.
63. Zhang, Z; **Stanley Jr, SL**. Stereotypic and specific elements of the human colonic response to *Entamoeba histolytica* and *Shigella flexneri*. *Cellular Microbiology*, 2004, June; 6(6):535-564.
64. Espinosa, A; Clark, DC; **Stanley Jr, SL**. *Entamoeba histolytica* alcohol dehydrogenase 2 (EhADH2) as a target for antiamebic agents. *Journal of Antimicrobial Chemotherapy*, 2004, July; 54(1):56-59.
65. Chen, M; Li, E; **Stanley Jr, SL**. Structural analysis of the acetaldehyde dehydrogenase activity of *Entamoeba histolytica* alcohol dehydrogenase 2 (EhADH2), a member of the ADHE enzyme family. *Molecular & Biochemical Parasitology*, 2004, October; 137(2):201-205.
66. Davis, PH; Zhang, Z; Chen, M; Zhang, XC; Chakraborty, S; **Stanley Jr, SL**. Identification of a family of Bsp-A like surface proteins of *Entamoeba histolytica* with novel leucine rich repeats. *Molecular & Biochemical Parasitology*, 2006, January; 145(1):111-116.
67. Pelosoff, L; Davis, PH; Zhang, Z; Zhang, XC; **Stanley Jr, SL**. Coordinate but disproportionate activation of apoptotic, regenerative, and inflammatory pathways characterizes the liver response to acute amebic infection. *Cellular Microbiology*, 2006, March; 8(3):508-522.
68. **Stanley Jr, SL**. The need for continuing vigilance: addressing the threat for transmission of blood-borne infectious disease. *Seminars in Hematology*, 2006, April; 43(3) Supplement: S17-S22.
69. Davis, PH; Zhang, X; Guo, J; Townsend, RR; **Stanley Jr, SL**. Comparative proteomic analysis of two *Entamoeba histolytica* strains with different virulence phenotypes identifies peroxiredoxin as an important component of amebic virulence. *Molecular Microbiology*, 2006, September; 61:1523-1532.
70. Ludlam, CA; Powderly, WG; Bozzett, S; Diamond, M; Koerper, MA; Kulkarni, R; Ritchie, B; Siegel, J; Simmonds, P; **Stanley Jr, SL**; Tapper, ML; von Depka, M. Clinical perspectives of emerging pathogens in bleeding disorders. *Lancet*, 2006, January 21; 367(9506):252-261.
71. Davis, PA; Schulz, J; **Stanley Jr, SL**. Transcriptomic comparison of two *Entamoeba histolytica* strains with defined virulence phenotypes identifies new virulence factor candidates and key differences in the expression patterns of cysteine proteases, lectin light chains, and calmodulin. *Molecular & Biochemical Parasitology*, 2007, January; 151(1):118-128.
72. **Stanley Jr, SL**; Frey, SE; Taillon-Miller, P; Guo, J; Miller RD; Koboldt, DC; Elashoff, M; Christensen, R; Saccone, NL; Belshe, RB. The immunogenetics of smallpox vaccination. *Journal of Infectious Diseases*, 2007, July 15; 196(2): 212-219.

73. Lawrence, SJ; Lottenbach, KR; Newman, FK; Buller, RM; Bellone, CJ; Chen, JJ; Cohen, GH; Eisenberg, RJ; Belshe, RB; **Stanley Jr, SL**; Frey, SE. Antibody responses to vaccinia membrane proteins after smallpox vaccination. *Journal of Infectious Diseases*, 2007, July; 196(2):220-229.
74. Melendez-Lopez SG; Herdman, S; Hirata K; Choi, MH; Choe, Y; Craik, C; Caffrey, CR; Hansell, E; Chavez-Munguia, B; Chen, YT; Roush, WR; Mckerrow, J; Eckmann, L; Guo, J; **Stanley Jr, SL**; Reed, SL. Use of recombinant *Entamoeba histolytica* cysteine proteinase 1 to identify a potent inhibitor of amebic invasion in a human colonic model. *Eukaryotic Cell*, 2007, July; 6(7):1130-1136.
75. Bullok, KE; Maxwell, D; Kesarwala, AH; Gammon, S; Prior, JL; Snow, M; **Stanley, S**; Piwnicka-Worms, D. Biochemical and in vivo characterization of a small membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. *Biochemistry*, 2007, April 3; 46(13): 4055-4065.
76. Snow, M; Chen, M; Guo, J; Atkinson, J; **Stanley Jr, SL**. Differences in complement-mediated killing of *Entamoeba histolytica* between men and women—an explanation for the increased susceptibility of men to invasive amebiasis? *American Journal of Tropical Medicine and Hygiene*. 2008, June; 78(6): 922-923.
77. Sarder, P; Nehorai, A; Davis, PH; **Stanley Jr, SL**. Estimating gene signals from noisy microarray images. *IEEE Transactions on NanoBioscience*. 2008, June, 7(2):142-153.
78. Sperandio, B; Regnault, B; Guo, J; Zhang, Z; **Stanley Jr, SL**; Sansonetti, PJ; Pedron, T. Virulent *Shigella flexneri* subverts the host innate immune response through the manipulation of antimicrobial peptide gene expression. *Journal of Experimental Medicine*, 2008, May 12; 205(5):1121-32. PMID 18426984.
79. Davis, P; Chen, M; Zhang, X; Clark, CG; Townsend, RR; **Stanley Jr, SL**. Proteomic comparison of *Entamoeba histolytica* and *Entamoeba dispar* and the Role of *E. histolytica* alcohol dehydrogenase 3 in Virulence. *PLOS Neglected Tropical Diseases*, 2009, 3(4): e415. Epub, 2009, April 14. PMID: 19365541.
80. Biller, L; Davis, PH; Tillack, M; Matthiesen, J; Lotter, H; **Stanley Jr, SL**; Tannich, E; Bruchhaus, I. Differences in the transcriptome signatures of two genetically related *Entamoeba histolytica* cell lines derived from the same isolate with different pathogenic properties. *BMC Genomics*, 2010, January 26; 11:63. PMID: 20102605.
81. Otero, K; Turnbull, IR; Poliani, PL; Vermi W; Cerutti E; Aoshi T; Tassi I; Takai T; **Stanley Jr, SL**; Miller M; Shaw AS; Colonna M. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. *Natural Immunology*, 2009, July 10(7):734-43. Epub 2009 June 7. PMID 19503107.

#### REVIEWS AND INVITED PUBLICATIONS

1. **Stanley Jr, SL**; Davie, JM. "Production and function of rheumatoid factors in the normal immune response." *Contribution to Microbiology Immunology*, 1989; 11:151-187.
2. Li, E; **Stanley Jr, SL**. "The role of newer antibiotics in gastroenterology." *Gastroenterology Clinics of North America*, 1992; 21: 613-631.
3. **Stanley Jr, SL**; Burch, DJ; Cieslak, P. "New diagnostic techniques in amebiasis." *LabMedica International* 1992; 9:7-10.
4. **Stanley Jr, SL**. "Amebiasis" in *Conn's Current Therapy*. R.E. Rakel, Ed. W.B. Saunders Company, Philadelphia, pp. 60-62, 1993.
5. **Stanley Jr, SL**; Li, E. "Pathophysiology of Amebiasis." *Seminars in Gastrointestinal Disease* 1993; 4:214-223.
6. **Stanley Jr, SL**; Virgin, IV, HW. "Scid mice as models for helminth and protozoan diseases." *Parasitology Today* 1993; 9:406-412.
7. **Stanley Jr, SL**. "Susceptibility testing and acquired drug resistance in parasitic diseases" in *Handbook of Clinical Microbiology*, Washington, D.C., P. R. Murray, Ed. ASM Press. pp. 1424-1427, 1995.
8. Li, E; **Stanley Jr, SL**. "Parasitic diseases of the GI tract." *Current Opinion in Gastroenterology*, 1995; 11:63-68.
9. Li, E; **Stanley Jr, SL**. "Amebiasis." *Gastroenterology Clinics of North America*, 1996; 25:471-492.
10. Seydel, K; **Stanley Jr, SL**. "Scid mouse models for parasitic diseases." *Clinical Microbiology Review*, 1996; 9:126-134.
11. **Stanley Jr, SL**. "Progress in a vaccine for amebiasis." *Parasitology Today*. 1996; 12:7-14.
12. Sultan, F; **Stanley Jr, SL**. "Amebiasis" in *Current Diagnosis* 9, edited by Conn, RB, Borer, WZ, and Snyder, JW. Philadelphia, W.B. Saunders, pp. 225-227, 1997.
13. **Stanley Jr, SL**. "Progress towards development of a vaccine for amebiasis." *Clinical Microbiology Review*, 1997, October; 10(4):637-649.
14. **Stanley Jr, SL**. "Malaria vaccines: Are seven antigens better than one?" *Lancet* 352 (9135):1163-1164, 1998.

15. **Stanley Jr, SL.** “Advice to travelers” in *Textbook of Gastroenterology*, 3rd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 1145-1159, 1999.
16. **Stanley Jr, SL.** “Advice to travelers” in *Atlas of Gastroenterology*, 2nd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 127-138, 1999.
17. Li, E; **Stanley Jr, SL.** “Parasitic diseases—protozoa” in *Textbook of Gastroenterology*, 3rd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 2423-2441, 1999.
18. Li, E; **Stanley Jr, SL.** “Parasitic diseases—protozoa” in *Atlas of Gastroenterology*, 2nd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 516-526, 1999.
19. **Stanley Jr, SL.** “Prevention of amebiasis and potential of new interventions” in *Amebiasis*, edited by Ravdin, J.I. London, Imperial College Press, pp. 137-163, 2000.
20. **Stanley Jr, SL; Zhang, T; Seydel, KB.** “Animal models of amebiasis” in *Handbook of Animal Models of Infection*, edited by Zak, O, and Sande, M. London, Academic Press, pp. 859-865, 2000.
21. **Stanley Jr, SL.** “Extraintestinal amebiasis” in *Current Therapy for Infectious Diseases*, Edited by Schlossberg, D., St. Louis, Mosby, Inc. pp. 693-695, 2001.
22. **Stanley Jr, SL; Li, E.** “Amoebiasis” in *Encyclopedia of Life Sciences*. London, Macmillan Reference Limited. 2001.
23. **Stanley Jr, SL.** “Pathophysiology of amebiasis.” *Trends in Parasitology* (formerly *Parasitology Today*). 2001; 17:280-285.
24. **Stanley Jr, SL; Reed, SL.** “*Entamoeba histolytica*: parasite-host interactions.” *American Journal of Physiology–Gastrointestinal & Liver Physiology*. 2001, June; 280: G1049-G1054.
25. **Stanley Jr, SL.** “Protective immunity to amebiasis: New insights and new challenges.” *Journal of Infectious Diseases*, 2001; 184:504-506.
26. **Stanley Jr, SL.** “Amebiasis.” *Pier Module*. 2002. www.pier
27. **Stanley Jr, SL.** “Pathways for amebic induction of inflammation and programmed cell death.” *Journal of Parasitology*, 2003; 89:S182-S188.
28. **Stanley Jr, SL.** “Amoebiasis.” *Lancet*, 2003, March 22; 361(9362):1025-34.
29. **Stanley Jr, SL.** “Advice to travelers” in *Textbook of Gastroenterology*, 4th Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 1120-1134, 2003.
30. **Stanley Jr, SL.** “Advice to travelers” in *Atlas of Gastroenterology*, 3rd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 153-162, 2003.
31. Li, E; **Stanley Jr, SL.** “Parasitic diseases—protozoa” in *Textbook of Gastroenterology*, 4th Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp. 2589-2607, 2003.
32. Li, E; **Stanley Jr, SL.** “Parasitic diseases—protozoa” in *Atlas of Gastroenterology*, 3rd Edition, edited by Yamada, T. Philadelphia, Lippincott-Raven, pp: 749-760, 2003.
33. Davis, P; **Stanley Jr, SL.** “Breaking the species barrier: use of mouse-human chimeras to study human infectious diseases.” *Cellular Microbiology*, 2003, December; 5(12):849-860.
34. **Stanley Jr, SL.** “Antiparasitic agents” in *Infectious Diseases*, 2nd Edition, edited by Cohen, J., and Powderly, W. London, Mosby, pp. 1941-1960, 2004.
35. **Stanley Jr, SL.** “Amebiasis” in *Encyclopedia of Gastroenterology*. San Diego, Elsevier, pp. 52-57, 2004.
36. **Stanley Jr, SL.** “The *Entamoeba histolytica* genome: something old, something new, something borrowed, and sex too?” *Trends in Parasitology*, 2005, October; 21(10):451-453.
37. Phillips, M; **Stanley Jr, SL** “Chemotherapy of protozoal infections” in Goodman and Gilman’s *Pharmacological Basis of Therapeutics*, 11th Edition, edited by Lazo, JS, Parker, K, Brunton, LL, Goodman, LS and Gilman, A. New York, McGraw Hill, 2005.
38. Snow, M; **Stanley Jr, SL.** “Recent progress in vaccines for amebiasis.” *Archives of Medical Research*, 2006, February; 37(2):280-287.
39. **Stanley Jr, SL.** “Vaccines for amoebiasis: barriers and opportunities.” *Parasitology*, 2006; 133:S81-86.
40. **Stanley Jr, SL.** “Antiparasitic agents” in *Infectious Diseases*, 3rd Edition, edited by Cohen, J, Powderly, W, Opal, S.M., Mosby, Chapter 150, 2010.
41. Phillips, M; **Stanley Jr, SL** “Chemotherapy of protozoal infections” in Goodman and Gilman’s *Pharmacological Basis of Therapeutics*, 12th Edition, edited by Brunton, LL, Chabner, B, Knollmann, B, New York, McGraw Hill, in press.

## PATENTS

U.S. Patent 5,130,147: *Entamoeba histolytica* Immunogenic protein and cDNA clone

Significance: Patent of the SREHP cDNA clone; recombinant SREHP is a major vaccine candidate for amebiasis, and a reagent utilized in prototype diagnostic tests.

Inventor: Samuel L. Stanley Jr. and Ellen Li

Assignee: Washington University, St. Louis

U.S. Patent 5,275,935: Amebic glycoconjugate and monoclonal antibody

Significance: Patent of the amebic glycoconjugate, a major surface antigen of amebae and a monoclonal antibody, CC 8.6 which recognizes this antigen. Possible uses in diagnostic kits.

Inventor: Samuel L. Stanley Jr. and Ellen Li

Assignee: Washington University, St. Louis

U.S. Patent 5,807,000: Method of screening anti-amebic compounds

Significance: Describes the use of mutant *E. coli* strains complemented with amebic antigens to screen compounds for anti-amebic activity.

Inventor: Samuel L. Stanley Jr.

Assignee: Washington University, St. Louis